μ阿片受体激动剂研究进展
Research Progress of μ-Opioid Receptor Agonist

上世纪60年代，新型镇痛剂芬太尼的发现引起了各国科学家们对新型镇痛药研究的热潮，人们开始研究吗啡及与吗啡结构相似的芬太尼这类新型镇痛剂的药理作用，生物活性等。自从70年代发现脑内存在阿片受体和内源性阿片肽以来，各国学者都开始积极研究阿片受体的结构。阿片受体主要有μ、δ、κ三种类型，其中，μ受体也是吗啡，芬太尼等镇痛药主要作用的受体蛋白位点。继芬太尼的发现之后，人们又发现了许多其他具有高活性的芬太尼类似物，如羟甲芬太尼(OMF)等。近年来，许多研究都表明敲除δ-阿片受体或者使用阿片类拮抗剂可以减轻或者抑制μ阿片镇痛药长期服用导致的耐受力和药物依赖性。

Abstract: In the 1960s, the discovery of new analgesic fentanyl caused the boom of new analgesic study around the world; people began to study pharmacological effects, biological activity and other characters of the new analgesic of morphine and fentanyl, which is similar to morphine on structure. Since the 1970s, the existence of opioid receptors and endogenous opioid peptides has been found in the brain; many scholars have begun to study the structure of opioid receptor actively. There are mainly three types of opioid receptors (μ, δ, κ), and wherein, μ receptor protein is the primary receptor site of morphine, fentanyl and other analgesics. Following the discovery of fentanyl, many other highly active fentanyl analogs have been found, such as Ohmefentanyl (OMF). Recently, many studies have shown that gene knock-out of δ-opioid receptor or antagonists can reduce or suppress tolerance and drug dependency—the side effects of μ-opioid analgesics for long-term administration.

[1] Janssen, P.A.J. (1962) A review of the chemical features associated with strong morphine-like activity. British Journal of Anaesthesia, 34, 260.

[2] 孔令锁, 胡宪文, 张野 (2011) 阿片受体激动剂预处理对器官缺血/再灌注损伤的保护作用. 国际麻醉学与复苏杂志, 5, 600-603.

[3] Evans, C.J., Keith, D.E., Morison, H., et al. (1992) Cloning of a delta opioid receptor by functional expression. Science, 258, 1952-1955.

[4] Chen, Y., Mestek, A., Yu, L., et al. (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Molecular Pharmacology, 44, 8-12.

[5] 池志强 (1998) 阿片受体研究最新进展. 生命科学, 2, 90-93.

[6] 晏庭林, 李琳, 刘新社 (2009) 阿片受体及阿片肽研究进展. 中国药物依赖性杂志, 5, 375-379.

[7] Andersen, G. (2003) Relationships among morphine metabolism, pain and side effects during long-term treatment, an update. Journal of Pain and Symptom Management, 25, 74-91.

[8] Zadina, J.E. and Martin-Schild, S. (1999) Endomorphins, novel endogenous μ-opiate receptor agonists in regions of high μ-opiate receptor density. Annals New York Academy of Sciences, 897,136-144.

[9] Zadina, J.E., Hackler, L. and Ge, L.J. (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature, 386, 499-502.

[10] 任维华, 霍笑风, 吴宁 (2001) 内吗啡肽研究进展. 中国药理学通报, 1, 17-20.

[11] Liu, X., Wang, Y., Xing, Y.H., Yu, J., Ji, H., Kai, M., et al. (2013) Design, synthesis, and pharmaco-logical characterization of novel endomorphin-1 analogues as extremely potent μ-opioid agonists. Journal of Medicinal Chemistry, 56, 3102-3114.

[12] Narita, M., Ozaki, S. and Suzuki, T. (2002) Endomorphin-induced motivational effect: Differential mechanism of endomorphin-1 and endomorphin-2. Japanese Journal of Pharmacology, 89, 224-228.

[13] Horvath, G. (2000) Endomorphin-1 and endomorphin-2: Pharmacology of the selective endogenous μ-opioid receptor agonists. Pharmacology & Therapeutics, 88, 437-463.

[14] 李玉林, 徐筱杰 (1989) 芬太尼类化合物与阿片受体相互作用的构象分析. 物理化学学报, 6, 681-687.

[15] Yekkirala, A.S., Banks, M.L., Lunzer, M.M., Negus, S.S., Rice, K.C. and Portoghese, P.S. (2012) Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in rhesus monkeys. ACS Chemical Neuroscience, 3, 720-727.

[16] Weltrowska, G., Chung, N.N., Lemieux, C., et al. (2010) “Carba”-analogues of fentanyl are opioid receptor agonists. Journal of Medicinal Chemistry, 53, 2875-2881.

[17] 温素妲, 杨玉龙, 邵华宙, 张开镐, 李玉林, 陈冀胜 (1993) 4-甲氧羰基芬太尼非芳基类似物的合成及镇痛作用. 药学学报, 3, 181-187.

[18] 徐珩, 陈浩, 池志强 (1984) 羟甲芬太尼(Ohmefentanyl), 一个新的μ阿片受体激动剂. 中国科学, 8, 733-739.

[19] 池志强, 朱友成, 金文桥, 徐珩, 周德和, 叶淑珍 (1999) 羟甲芬太尼——一种新型的高选择性μ阿片受体激动剂. 中国科学基金, 4, 280-283.

[20] Healy, J.R., Bezawada, P., Shim, J., Jones, J.W., Kane, M.A., MacKerell, A.D., et al. (2013) Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ-agonist/δ-antagonist opioid analgesic with reduced tolerance liabilities. ACS Chemical Neuroscience, 4, 1256-1266.

[21] Balboni, G., Salvadori, S., Trapella, C., et al. (2010) Evolution of the bifunctional lead μ agonist/δ antagonist containing the 2’,6’-dimethyl-L-tyrosine-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Dmt-Tic) opioid pharmacophore. ACS Chemical Neuroscience, 1, 155-164.

[22] 胡文祥, 刘明 (2014) 阿片受体分子药学. 化学工业出版社, 北京.